Aurinia Pharmaceuticals Stock Forecast, Price & News

Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

Is Aurinia Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aurinia Pharmaceuticals stock.
View analyst ratings for Aurinia Pharmaceuticals or view top-rated stocks.

How has Aurinia Pharmaceuticals' stock been impacted by COVID-19?

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AUPH stock has increased by 47.7% and is now trading at $20.83.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 12,150,000 shares, a decrease of 29.1% from the October 14th total of 17,130,000 shares. Based on an average daily trading volume, of 4,320,000 shares, the days-to-cover ratio is presently 2.8 days. Currently, 11.4% of the company's stock are short sold.
View Aurinia Pharmaceuticals' Short Interest.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Aurinia Pharmaceuticals.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.06. The biotechnology company earned $14.67 million during the quarter, compared to analyst estimates of $14.70 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 44.22% and a negative net margin of 215.58%. During the same quarter in the prior year, the company earned ($0.28) EPS.
View Aurinia Pharmaceuticals' earnings history.

What price target have analysts set for AUPH?

6 brokerages have issued 12 month price targets for Aurinia Pharmaceuticals' stock. Their forecasts range from $23.00 to $40.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $33.17 in the next twelve months. This suggests a possible upside of 59.2% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:

• Mr. Peter S. Greenleaf M.B.A., Pres, CEO & Director (Age 51, Pay $1.39M)
• Mr. Joseph M. Miller C.P.A., Chief Financial Officer (Age 47, Pay $614.27k) (LinkedIn Profile)
• Mr. Matthew Maxwell Donley M.B.A., Exec. VP of Operations & Strategy (Age 52, Pay $627.51k) (LinkedIn Profile)
• Mr. Stephen P. Robertson, Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 39, Pay $193.43k)
• Mr. Massimiliano Colao, Chief Commercial Officer (Age 56, Pay $719.79k)
• Dr. Glenn Schulman, Sr. VP of Corp. Communications & Investor Relations
• Mr. Chris Hays, VP of Marketing
• Mr. Fran Lynch, VP of Sales
• Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C), Exec. VP of Research (Age 56)
• Mr. Michael R. Martin, Chief Bus. Officer (Age 49)

Who are some of Aurinia Pharmaceuticals' key competitors?

Some companies that are related to Aurinia Pharmaceuticals include Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), CureVac (CVAC), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), Mirati Therapeutics (MRTX), Grifols (GRFS) and Biohaven Pharmaceutical (BHVN).
View all of AUPH's competitors.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (5.22%), Citadel Advisors LLC (0.00%), BlackRock Inc. (0.70%), Kestra Private Wealth Services LLC (0.62%), Voloridge Investment Management LLC (0.49%) and Rock Springs Capital Management LP (0.48%). Company insiders that own Aurinia Pharmaceuticals stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends for Aurinia Pharmaceuticals.

Which institutional investors are selling Aurinia Pharmaceuticals stock?

AUPH stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Royal Bank of Canada, FIL Ltd, DG Capital Management LLC, DNB Asset Management AS, Altium Capital Management LP, International Biotechnology Trust PLC, and Rock Springs Capital Management LP. Company insiders that have sold Aurinia Pharmaceuticals company stock in the last year include Michael Robert Martin, Neil Solomons, and Robert Bindert Huizinga.
View insider buying and selling activity for Aurinia Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Kestra Private Wealth Services LLC, Voloridge Investment Management LLC, Deerfield Management Company L.P. Series C, Barclays PLC, Citadel Advisors LLC, BlackRock Inc., and SG Americas Securities LLC. Company insiders that have bought Aurinia Pharmaceuticals stock in the last two years include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Peter Greenleaf, and Stephen P Robertson.
View insider buying and selling activity for Aurinia Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $20.83.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals has a market capitalization of $2.67 billion and generates $50.12 million in revenue each year. The biotechnology company earns $-102.68 million in net income (profit) each year or ($1.21) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals employs 294 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Where are Aurinia Pharmaceuticals' headquarters?

Aurinia Pharmaceuticals is headquartered at 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272, via email at [email protected], or via fax at 250-744-2498.